From August 24, 2023 to September 30, 2023, the company has repurchased 533,100 shares, representing 0.49% for CNY 34.05 million. With this, the company has completed the repurchase of 533,100 shares, representing 0.49% for CNY 34.05 million under the buyback announced on August 24, 2023.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
Equities
301096
CNE1000056N5
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
60.85 CNY | -1.65% | -1.39% | -6.53% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.53% | 909M | |
+44.97% | 56.65B | |
-7.30% | 39.44B | |
+39.19% | 39.03B | |
-11.17% | 26.86B | |
+12.23% | 26.75B | |
-21.69% | 19.03B | |
+1.33% | 12.28B | |
+24.09% | 12.26B | |
+27.37% | 12.04B |
- Stock Market
- Equities
- 301096 Stock
- News Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
- Tranche Update on Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback Plan announced on August 24, 2023.